June 20th 2025
The phase 1 study is set to begin later this year.
The approval is supported by data from the pivotal phase 3 ARANOTE trial.
The approval is supported by several studies highlighting the efficacy of Rezūm Water Vapor Therapy in patients with larger prostates,
June 19th 2025
The conversation covers practical, case-based strategies for counseling MSM patients.
"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.
Phase 3 trial launches of ifinatamab deruxtecan vs chemotherapy in mCRPC
The IDeate-Prostate01 trial plans to enroll approximately 1440 patients whose tumors progressed following prior treatment with an ARPI.
FDA approves integrated sacral neuromodulation system for urinary urge incontinence
The approval is supported by landmark results from the pivotal phase 2 SANS-UUI trial.
Money Matters: A financial guide to approaching retirement
"Estimate how much you will need to spend each year during various stages of retirement," advises Ronald J. Paprocki, JD, CFP, CHBC.
Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
FDA does not approve talazoparib plus enzalutamide for non-HRR gene mutated mCRPC
Pfizer has chosen to no longer pursue an expanded indication for talazoparib plus enzalutamide in non-HRR gene mutated mCRPC in the US as a result of this decision.
Ultrasound imaging system now available to guide nonsurgical urology procedures
The bkActiv S series is designed to guide nonsurgical urologic, colorectal, and pelvic floor procedures.
CPT 49186 vs 38780: Coding retroperitoneal mass excision
"We believe the confusion comes from the typical lexicon surgeons use when performing surgeries, rather than the actual code descriptor and the procedure performed," write Jonathan Rubenstein, MD, and Mark Painter.
From BCG shortage to scientific surge: Inside the NMIBC treatment renaissance
Anne K. Schuckman, MD, describes the growing number of options in NMIBC and the impact of these therapies on clinical practice.
CHAI biomarkers demonstrate prognostic utility for high-grade Ta NMIBC
The CHAI biomarker was shown to outperform EAU and AUA stratifications.
Is there a difference between MD and DO in urology?
"Osteopathic urologists were more likely to work in private practice (58.4% vs 49.8%; P = .038) and in rural/nonmetropolitan areas (16.2% vs 8.7%; P = .002)," write the authors.
64Cu-SAR-Bombesin shows efficacy in detecting prostate cancer recurrence
The results from the SABRE trial are intended to support the design of a registrational trial of 64Cu-SAR-Bombesin.
From prep to follow-up: Key considerations for administering onabotulinumtoxinA
Benjamin M. Brucker, MD, discusses best practices for the onabotulinumtoxinA procedure, spanning all phases of treatment—before, during, and after administration.
FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC
The approval is supported by findings from the phase 3 ENVISION trial.
AI-based tool aims to optimize MRI use in prostate cancer diagnosis
"I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.
PSMA-PET imaging product, Gozellix, launches on US market
Gozellix was approved by the FDA in March 2025.
Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer
However, this regimen was associated with substantial toxicity, so careful patient selection is paramount, according to the authors.
Phase 2 trial of oncolytic immunotherapy launches in BCG-unresponsive NMIBC
The objectives of the trial are to further confirm the recommended phase 2 dose and to assess the efficacy of MVR-T3011.
FDA accepts new drug application for zoliflodacin for uncomplicated gonorrhea
The NDA is supported by a pivotal phase 3 trial of zoliflodacin vs ceftriaxone plus azithromycin in patients with uncomplicated gonorrhea.
Second-line cabozantinib shows efficacy in advanced renal cell carcinoma
The regimen showed activity regardless of the prior immunotherapy-based combination used in the first-line setting.
En bloc resection of bladder tumor: Is it the way forward?
"As urologists, we are the gatekeepers, and we must always perform the best possible surgery to optimize oncological outcomes," writes Jeremy Teoh, MBBS, FRCSEd (Urol), FCSHK, FHKAM (Surgery).
Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC
In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors.
FDA authorizes Expanded Access Program of Anktiva for lymphopenia
The Cancer BioShield platform is being assessed as a treatment for lymphopenia in adult patients with refractory or relapsed solid tumors, including genitourinary tumors.
Prostate cancer awareness in 2025: A human imperative in the wake of President Biden’s diagnosis
"As clinicians, researchers, and advocates, this moment invites us to reflect on how far we’ve come—and how much further we must go," writes Michael S. Cookson, MD, MMHC, FACS.
Pivotal trial of histotripsy system for kidney tumors reaches enrollment goal
Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.
Study finds racial/ethnic disparities in use of PSMA-PET in prostate cancer
Data showed that Non-Hispanic Black and Latinx/Hispanic patients were less likely to receive PSMA-PET imaging than non-Hispanic White patients.